Material Agreement (Form 8-K)

Item 1.01. Entry Into a Material Definitive Agreement.

On September 12, 2025 (the "Issue Date"), Glucotrack, Inc. (the "Company") entered into a Note Purchase Agreement (the "Note Purchase Agreement"), with an investor (the "Investor"), pursuant to which the Company issued a Convertible Promissory Note (the "Note") to the Investor in the principal amount of $3,600,000 for a purchase price of $3,000,000.

The Note bears no interest, has an original issue discount of $600,000, is an unsecured obligation of the Company and will rank equal in right of payment with the Company's existing and future unsecured indebtedness.

Unless converted earlier as set forth below, the Note will be due and payable on (i) the twelve (12) month anniversary of the Issue Date, or (ii) the date of closing of a Qualified Financing, as defined below. The Company may prepay the Note at any time without the requirement for consent of the Investor.

If not sooner repaid, all outstanding principal on the Note, as of the close of business on the day immediately preceding the date of the closing of the next issuance and sale of capital stock of the Company, in a single transaction or series of related transactions, to investors resulting in gross proceeds to the Company of at least $5,000,000 (excluding indebtedness converted in such financing) (a "Qualified Financing"), will, at the election of the Holder, be converted into that number of equity securities of the Company sold in the Qualified Financing equal to the number of securities calculated by dividing (i) the then outstanding principal balance of the Note by (ii) an amount equal to the price per share or other unit of equity securities issued in such Qualified Financing, and otherwise on the same terms as the security issued in the Qualified Financing, provided that the conversion price per share of common stock, par value $0.001 per share (the "Common Stock"), shall not, in any event, be lower than $4.87, subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations or other similar events (the "Floor Price").

As previously disclosed, on September 11, 2025, the Company entered into a purchase agreement with Sixth Borough Capital Fund, LP ("Sixth Borough") establishing an equity line of credit (the "ELOC"). Under the terms of the ELOC, the Company has the right, but not the obligation, to sell to the Sixth Borough, and Sixth Borough is obligated to purchase, up to $20.0 million of the Company's Common Stock (the "Purchase Shares"), subject to the terms and conditions set forth therein. Pursuant to the Note Purchase Agreement, the Company is required to pay 100% of the net proceeds (after commission) it receives from the sale of Purchase Shares under the ELOC towards repayment of the Note, until such time that the Company obtains stockholder approval (the "Stockholder Approval") to issue Purchase Shares in excess of the "Exchange Cap," as defined in the ELOC. Following Stockholder Approval, the Company is required to apply 50% of the net proceeds (after commissions) from any subsequent sales of Purchase Shares under the ELOC to repay the Note.

The Note contains certain specified events of default, the occurrence of which would entitle Investor to immediately demand repayment of all outstanding principal on the Note such as certain events of bankruptcy and insolvency. The Note does not contain any affirmative and restrictive covenants by the Company. The Purchase Agreement includes customary representations, warranties, and conditions precedent of both parties.

The Note was issued in a private placement to the Investor pursuant to an exemption for transactions by an issuer not involving a public offering under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act").

The foregoing description of the Note Purchase Agreement and the Note does not purport to be complete and is qualified in its entirety by reference to the Note Purchase Agreement and the Note, forms of each of which are filed herewith as Exhibit 10.1 and Exhibit 4.1, respectively, and incorporated herein by reference.